These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38702528)

  • 41. Comparison of Long-Term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis Between Dupilumab-Exposed and Dupilumab-Naïve Patients.
    Napolitano M; Ferrucci SM; Foggia L; Hansel K; Pezzolo E; Stingeni L; Antonelli E; Picone V; Patruno C
    Clin Drug Investig; 2024 Jan; 44(1):71-77. PubMed ID: 38105393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany.
    Heratizadeh A; Haufe E; Stölzl D; Abraham S; Heinrich L; Kleinheinz A; Wollenberg A; Weisshaar E; Augustin M; Wiemers F; Zink A; von Kiedrowski R; Hilgers M; Worm M; Pawlak M; Sticherling M; Fell I; Handrick C; Schäkel K; Staubach-Renz P; Asmussen A; Schwarz B; Bell M; Effendy I; Bieber T; Homey B; Gerlach B; Tchitcherina E; Stahl M; Schwichtenberg U; Rossbacher J; Buck P; Mempel M; Beissert S; Biedermann T; Weidinger S; Schmitt J; Werfel T;
    J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1263-1272. PubMed ID: 31721316
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial.
    Paller AS; Flohr C; Cork M; Bewley A; Blauvelt A; Hong HC; Imafuku S; Schuttelaar MLA; Simpson EL; Soong W; Arlert P; Lophaven KW; Kurbasic A; Soldbro L; Vest NS; Wollenberg A
    JAMA Dermatol; 2023 Jun; 159(6):596-605. PubMed ID: 37074705
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
    Simpson EL; Blauvelt A; Silverberg JI; Cork MJ; Katoh N; Mark T; Schneider SKR; Wollenberg A
    Am J Clin Dermatol; 2024 Jan; 25(1):139-148. PubMed ID: 37804473
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.
    Faiz S; Giovannelli J; Podevin C; Jachiet M; Bouaziz JD; Reguiai Z; Nosbaum A; Lasek A; Ferrier le Bouedec MC; Du Thanh A; Raison-Peyron N; Tetart F; Duval-Modeste AB; Misery L; Aubin F; Dompmartin A; Morice C; Droitcourt C; Soria A; Arnault JP; Delaunay J; Mahé E; Richard MA; Schoeffler A; Lacour JP; Begon E; Walter-Lepage A; Dillies AS; Rappelle-Duruy S; Barete S; Bellon N; Bénéton N; Valois A; Barbarot S; Sénéchal J; Staumont-Sallé D;
    J Am Acad Dermatol; 2019 Jul; 81(1):143-151. PubMed ID: 30825533
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study.
    Nettis E; Ferrucci SM; Ortoncelli M; Pellacani G; Foti C; Di Leo E; Patruno C; Rongioletti F; Argenziano G; Macchia L; Tavecchio S; Napolitano M; Ribero S; Bonzano L; Romita P; Di Bona D; Nisticò SP; Piras V; Calabrese G; Detoraki C; Carbonara M; Fabbrocini G
    J Investig Allergol Clin Immunol; 2022 Apr; 32(2):124-132. PubMed ID: 32856595
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis.
    Thyssen JP; Bieber T; Kleyn CE; Nosbaum A; Grond S; Petto H; Riedl E; Wollenberg A
    J Dermatolog Treat; 2023 Dec; 34(1):2216322. PubMed ID: 37345379
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry.
    Silverberg JI; Shi VY; Alexis A; Pierce E; Cronin A; McLean RR; Roberts-Toler C; Rueda MJ; Atwater AR; Simpson E
    Dermatol Ther (Heidelb); 2023 Sep; 13(9):2045-2061. PubMed ID: 37481484
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review.
    Iannone M; Tonini G; Janowska A; Dini V; Romanelli M
    Curr Med Res Opin; 2021 Aug; 37(8):1295-1301. PubMed ID: 34027753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD): Baseline treatment patterns and unmet needs assessment.
    Wei W; Ghorayeb E; Andria M; Walker V; Schnitzer J; Kennedy M; Chen Z; Belland A; White J; Silverberg JI
    Ann Allergy Asthma Immunol; 2019 Oct; 123(4):381-388.e2. PubMed ID: 31325566
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis.
    Silverberg JI; Gelfand JM; Margolis DJ; Fonacier L; Boguniewicz M; Schwartz LB; Simpson E; Grayson MH; Ong PY; Fuxench ZCC
    Ann Allergy Asthma Immunol; 2018 Oct; 121(4):464-468.e3. PubMed ID: 30003968
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The humanistic and economic burden of atopic dermatitis among adults and adolescents in Saudi Arabia.
    Elezbawy B; Fasseeh AN; Fouly E; Esba LCA; Al Abdulkarim H; Al-Haddab M; Al-Sheikh A; Altawil E; Al Turaiki A; Eshmawi M; Hamadah I; Tannira M; Dalle H; Aderian S; Roshdy A; Jaheen A; Hamad T; Abaza S; Kaló Z
    J Med Econ; 2022; 25(1):1231-1239. PubMed ID: 36426726
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany.
    Schmitt J; Abraham S; Trautmann F; Stephan V; Fölster-Holst R; Homey B; Bieber T; Novak N; Sticherling M; Augustin M; Kleinheinz A; Elsner P; Weidinger S; Werfel T
    J Dtsch Dermatol Ges; 2017 Jan; 15(1):49-59. PubMed ID: 27862987
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
    Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
    Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: A systematic review and meta-analysis.
    Lee HH; Patel KR; Rastogi S; Singam V; Vakharia PP; Chopra R; Silverberg JI
    J Am Acad Dermatol; 2020 Jan; 82(1):62-71. PubMed ID: 31202874
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
    Paller AS; Flohr C; Eichenfield LF; Irvine AD; Weisman J; Soung J; Pinto Correia A; Natalie CR; Rodriguez Capriles C; Pierce E; Reifeis S; Gontijo Lima R; Armengol Tubau C; Laquer V; Weidinger S
    Dermatol Ther (Heidelb); 2023 Jul; 13(7):1517-1534. PubMed ID: 37318750
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation.
    Schmitt J; Langan S; Deckert S; Svensson A; von Kobyletzki L; Thomas K; Spuls P;
    J Allergy Clin Immunol; 2013 Dec; 132(6):1337-47. PubMed ID: 24035157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psychosocial burden of patients with atopic dermatitis at two tertiary referral centres in Malaysia.
    Tan WF; Voo SYM; Sulaiman N; Robinson S
    Med J Malaysia; 2021 Sep; 76(5):643-652. PubMed ID: 34508369
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.